Eli Lilly announced plans to increase drug prices in Europe and other developed markets in response to the U.S. government's “most-favored-nation” policy under the Trump administration, aiming to balance drug costs across countries. This includes a dramatic hike in the list price of its obesity drug Mounjaro in the UK. Concurrently, legal and lobbying efforts continue surrounding Medicare's drug price negotiation program. These developments reflect growing tensions in pharmaceutical pricing and regulatory landscapes.